BioMarin to initiate BMN-111 Stage 1 trial in achondroplasia BioMarin Pharmaceutical Inc.

BioMarin to initiate BMN-111 Stage 1 trial in achondroplasia BioMarin Pharmaceutical Inc. announced today that the Investigational New Medication program for BMN-111, an analog of C-type Natriuretic Peptide , for achondroplasia is active levitra tablets 20 mg http://vardenafilcanadian.com . BMN-111 offers demonstrated benefits in moderately and severely affected pet versions and has been proven to market bone growth also in normal pets, mentioned Hank Fuchs, M.D. The principal objective of the Stage 1 trial is certainly to assess the basic safety and tolerability of one and multiple dosages of BMN-111 in normal adult healthful volunteers up to the utmost tolerated dose..

http://vardenafilcanadian.com

BioMarin commences GALNS Stage 2 research in mucopolysaccharidosis IVA BioMarin Pharmaceutical Inc. today announced the initiation of a Stage 2 research for GALNS in individuals under five years with mucopolysaccharidosis IVA .D., Chief Medical Officer of BioMarin.’ The principal objective of the Stage 2, open-label, multinational medical study is to judge the security and tolerability of infusions of GALNS at a dosage of 2.0 mg/kg/week over a 52-week period in ten to fifteen MPS IVA sufferers under five years.